Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanofi Genzyme
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
Sanofi wants the European Medicines Agency to re-examine its opinion that the company’s drug for Pompe disease does not qualify as a new active substance.
Celltrion has won a Brazilian tender to supply two oncology biosimilars – Herzuma (trastuzumab) and Truxima (rituximab) – to the Brazilian market. Based on its successful bid in Brazil, the company plans on expanding its direct sales business model to Peru and Chile in the third quarter of this year.
The European Medicines Agency decided this month whether to grant fast-track review for planned marketing authorization applications for three potential new orphan treatments.
- Other Names / Subsidiaries
- ILEX Oncology, Inc.
- Sangstat Medical Corporation
- Genzyme Corporation